Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bishnu Joshi

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|November 8, 2019
TCR Fingerprinting and Off-Target Peptide IdentificationArmen R Karapetyan, Chawaree Chaipan, Katharina Winkelbach, et al.
Current Microbiology|June 15, 2017
Comparative Study of GeneXpert MTB/RIF Assay and Multiplex PCR Assay for Direct Detection of Mycobacterium tuberculosis in Suspected Pulmonary Tuberculosis PatientsAnil Kumar Sah, Bishnu Joshi, Dhruba Kumar Khadka, et al.
Gastroenterology|July 20, 2010
Affinity peptide for targeted detection of dysplasia in Barrett's esophagusMeng Li, Constantinos P Anastassiades, Bishnu Joshi, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Bacteriophage-mediated reduction of uropathogenic <i>E. coli</i> from the urogenital epitheliumBishnu Joshi, Jacob J Zulk, Camille Serchejian, et al.
Infection and Immunity|February 26, 2026
Bacteriophage-mediated reduction of uropathogenic <i>E. coli</i> from the urogenital epitheliumBishnu Joshi, Jacob J Zulk, Camille Serchejian, et al.
Antioxidants & Redox Signaling|August 19, 2021
Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for <i>In Vivo</i> Detection of Sessile Serrated AdenomasSangeeta Jaiswal, Bishnu Joshi, Jing Chen, et al.
Nature Communications|June 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicityYury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
Iscience|February 16, 2024
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell cultureXiangmin Lv, Jesse Martin, Heather Hoover, et al.
Cancer Immunology Research|November 14, 2025
The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunityEleni Chantzoura, Efrat Altman-Sharoni, Xavier Michelet, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|November 8, 2019
TCR Fingerprinting and Off-Target Peptide IdentificationArmen R Karapetyan, Chawaree Chaipan, Katharina Winkelbach, et al.
Current Microbiology|June 15, 2017
Comparative Study of GeneXpert MTB/RIF Assay and Multiplex PCR Assay for Direct Detection of Mycobacterium tuberculosis in Suspected Pulmonary Tuberculosis PatientsAnil Kumar Sah, Bishnu Joshi, Dhruba Kumar Khadka, et al.
Gastroenterology|July 20, 2010
Affinity peptide for targeted detection of dysplasia in Barrett's esophagusMeng Li, Constantinos P Anastassiades, Bishnu Joshi, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Bacteriophage-mediated reduction of uropathogenic <i>E. coli</i> from the urogenital epitheliumBishnu Joshi, Jacob J Zulk, Camille Serchejian, et al.
Infection and Immunity|February 26, 2026
Bacteriophage-mediated reduction of uropathogenic <i>E. coli</i> from the urogenital epitheliumBishnu Joshi, Jacob J Zulk, Camille Serchejian, et al.
Antioxidants & Redox Signaling|August 19, 2021
Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for <i>In Vivo</i> Detection of Sessile Serrated AdenomasSangeeta Jaiswal, Bishnu Joshi, Jing Chen, et al.
Nature Communications|June 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicityYury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
Iscience|February 16, 2024
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell cultureXiangmin Lv, Jesse Martin, Heather Hoover, et al.
Cancer Immunology Research|November 14, 2025
The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunityEleni Chantzoura, Efrat Altman-Sharoni, Xavier Michelet, et al.
Pageof 3